© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
September 15, 2020
Sumanta K. Pal, MD, discusses the rationale behind the phase 3 TIVO-3 trial with tivozanib in advanced renal cell carcinoma.
September 10, 2020
Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.
June 24, 2020
Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.
February 11, 2020
Sumanta Kumar Pal, MD, discusses the potential use of PARP inhibitors in renal cell carcinoma.